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CONCLUSIONS: The design of VBID initiatives in MS can inform outcomes and
contracting strategies for manufacturers of MS therapies.
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INTERCONNECTED HTA MAP FOR ALZHEIMER’S DISEASE – ANALYSIS OF
DIVERGENCE AND COLLABORATION PATTERNS
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OBJECTIVES: To gain insights into technology assessments of Alzheimer’s disease
and to reveal the diverse influences on reimbursement decisions in the intercon-
nected HTA universe. METHODS: Eighty-four reports published by twenty two
Health Technology Assessment (HTA) agencies between 2000 and 2012 were iden-
tified that evaluate treatments for Alzheimer’s disease (fifty eight of them assessed
pharmaceuticals). Data extracted from those reports was supplemented with pub-
lished information from other sources and divided into data categories (agencies,
institutions, assessments, and people). Multiple attributes such as location, affili-
ation, membership, type of technology, decision on technology, degree of influ-
ence, type of influencewere assigned to each category and to connections between
them. The visual analysis software and social networking analysis techniques
were applied to this complex and densely interconnected dataset to observe the
engagement and influence of various actors in reimbursement decisions.
RESULTS: The visual analysis enabled to reveal commonalities and differences of
approaches in evaluating Alzheimer’s treatments between agencies (decisions vs
patient population, decision drivers). It also allowed identifying patterns of collab-
oration on specific assessments where agencies were referring to each other, re-
ferring to the same sources such as Cochrane reviews, European Collaboration
Initiatives (Alzheimer Europe, European Federation of Neurological Societies, Eu-
ropean Medicines Agency Guideline), professional association guidelines (Alzhei-
mer disease association, American College of Physicians). CONCLUSIONS: Alzhei-
mer’s disease HTA pathway is known for the disparities in decisions and
approaches among agencies. Applying social network analysis allowed identifica-
tion of patterns ofmutual influence and indirect collaboration in the bigger context
of these decisions.
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OBJECTIVES: To assess the utility of comparative effectiveness research in guiding
the development of outcome based contracts.METHODS: The I3 InVision database
was utilized to identify continuously enrolled patients between 18 and 64 years of
age with 2 diagnoses of multiple sclerosis (MS) (ICD-9-CM of 340.xx).Receipt of a
disease modifying therapy (DMT), with first such date was identified as the index
date. Severe relapsewas defined as either 1) a patient hospitalizedwith a diagnosis
of MS in the post-period or a patient receiving a claim of an outpatient visit with
accompanying use of IVmethylprednisolone. Univariate statistics (ANOVAandChi
Square) were used to compare baseline patient characteristics.The probability of
relapse was assessed using logistic controlling for patient characteristics (age, sex,
region of residence, and insurance product), intent-to-treat, disease modifying
therapy, general health (Charlson Index, medical ADL, prior relapse), and medica-
tion possession ratio (MPR). Differences in charges between the three groups were
assessed using a generalized linear model with gamma distribution and log-link.
RESULTS:A total of 2302 continuously enrolled patientsmet study criteria between
the dates of January 1, 2006 through March 31, 2011. Fourteen percent (14.54%; n 
333) and 13.79% of patients experienced a severe relapse requiring hospitalization
and/or outpatient IV Methylprednisolone use, respectively.Univariate statistics re-
vealed differences across groups with individuals with higher pre-period Charlson
Index (p  0.001), higher pre-period Medical ADL limitation proxy (p  0.001) and
higher numbers of pre-period severe relapse (p  0.001). Lower MPR across the
duration of the post period (p  0.001) and patients enrolled in independent or
preferred provider organization (p  0.001) more likely to experience a severe re-
lapse in the post-period. CONCLUSIONS: Comparative Effectiveness Research
(CER) is an important tool that can be beneficial to inform the design and imple-
mentation of outcome based contracting between health plans and pharmaceuti-
cal manufacturers.
NEUROLOGICAL DISORDERS – Research on Methods
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IDENTIFYING A CONDITION WITH NO ICD-9-CM DIAGNOSIS CODE FROM
ADMINISTRATIVE CLAIMS DATA: POST-STROKE PATIENTS WITH
PSEUDOBULBAR AFFECT
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OBJECTIVES: Pseudobulbar affect (PBA) is a neurological condition characterized by
uncontrolled outbursts of laughter or crying. It occurs secondary to brain injury or
neurologic disease. PBA is often confused with other mental health (MH) condi-
tions, and is challenging to identify retrospectively with claims data because an
ICD-9-CM diagnosis code was not designated until late 2011. PBA is often treated
with antidepressants, anticonvulsants, antipsychotics, or anxiolytics. Estimated
prevalence of PBA secondary to stroke is 7% to 50%. Our study objective was to
identify PBA in a population of post-stroke patients. METHODS: Commercial and
Medicare Advantage members with incident stroke from January 1, 2007 to Febru-
ary 28, 2010 were identified with retrospective claims data from a large US health
plan. Patients were continuously enrolled for 12 months pre- and post-stroke.
Those with: stroke care, MH conditions (depression, bipolar, generalized anxiety or
personality disorders), antidepressants, or diagnoses of emotional lability (ICD-9
799.24, 310.8x) pre-stroke were excluded. Post-stroke PBA was identified with:
ICD-9 codes for emotional lability;1 MH-related ambulatory visit; or1 claim for
a selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine
reuptake inhibitor (SNRI) plus 1 claim for anticonvulsant, antipsychotic, or anx-
iolytic within 6months post-stroke. Sensitivity of the criteria was tested by requir-
ing more medication claims or adding MH-related hospitalization. RESULTS: The
study population comprised 9408 post-stroke patients. The PBA criteria identified
605 (10.3%) of commercial and 253 (7.1%) ofMedicare Advantage subjects. Less than
1% had diagnoses indicating emotional lability. Stricter medication criteria re-
duced the PBA cohort2 percentage points, indicating most patients hadmultiple
SSRI, SNRI, and other medication fills. MH-related hospitalizations increased the
PBA cohort 1 percentage point. Overall, 8.6-11.1% of commercial and 6.6-7.9% of
Medicare Advantage patients had potential PBA, depending on criteria.
CONCLUSIONS: The criteria identified a stable potential PBA cohort within the
range of estimated PBA prevalence.
URINARY/KIDNEY DISORDERS – Clinical Outcomes Studies
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THE EFFECT OF COADMINSTRATION OF NICOTINAMIDE AND CALCIUM-BASED
PHOSPHATE BINDER ON HYPERPHOPHATEMIA IN PATIENTS UNDERGOING
HEMODIALYSIS
Allam S1, El-Hamamsy M2, El Sharkawy M2
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OBJECTIVES:Assessment the safety and the efficacy of nicotinamide as adjunctive
therapy to calcium carbonate (as phosphate binder).METHODS: Study design and
setting: A prospective, interventional, open-labeled, case control randomized trial
was performed at Ain Shams University Specialized Hospital and Al Motamayz
hemodialysis center, Cairo, Egypt, from August 2010 to December 2010.
PATIENTS AND METHODS: Sixty hemodialysis patients with serum phosphorus
level  5.0 mg/dl were classified into two groups; group I (control group) in which
patients received calcium carbonate tablets in dose of 500mg to 1000mg three t.i.d.
And group II (study group) in which patients received calcium carbonate in dose of
500mg to 1000mg t.i.d. and nicotinamide tablets in a dose titrated to 1000mg/day
for 8 weeks. Serum calcium, phosphorus and intact parathyroid hormone were
measured at week 1 and 9 to assess the efficacy of treatment. RESULTS: Fifty-six
patients successfully completed the trail. Serum phosphorus level falls signifi-
cantly from 6.75 to 5.47 mg/dl with group II and not with group I (from 6.46 to 6.53
mg/dl). A concurrent fall in calcium- phosphorus product was seen with nicotin-
amide treatment (from 58.7 to 48.55mg2/dl2), whereas serum calcium, intact para-
thyroid hormone, uric acid, platelet count, total cholesterol, hemoglobin, AST, and
ALT remained stable in both arms. A trend toward increasing HDL and reducing
LDL and triglycerides were reported in nicotinamide group however the overall
changes were statistically non significant. Diarrhea and other gastrointestinal dis-
turbances symptoms were the major adverse effects seen with nicotinamide
treatment. CONCLUSIONS:Nicotinamide in single dose of 1000mg daily can effec-
tively reduce serum phosphorus level when administered with calcium carbonate
(as phosphate binder) with less potential side effects.
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ODDS OF MISSED HEMODIALYSIS SESSIONS ARE INCREASED DURING HOLIDAY
PERIODS AMONG IN-CENTER HEMODIALYSIS PATIENTS
Crawford SO, Wang X, Oberai PC, Sibbel SP
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OBJECTIVES: Missed dialysis sessions place a significant economic burden on di-
alysis facilities, compromising dialysis delivery and increasing the cost of hemo-
dialysis. Longer interdialytic intervals have been shown to increase morbidity and
mortality and may result in increased time on dialysis. We therefore assessed the
likelihood of missed dialysis sessions during holiday periods, which may prolong
interdialytic intervals. METHODS: We evaluated missed sessions during holiday
and non-holiday periods among 2474 in-center hemodialysis patients from 2006-
2010. We assessed 5 holidays (Memorial day, Independence Day, Labor Day,
Thanksgiving, and Christmas/New Years) and compared the proportion of missed
sessions in the week surrounding the holiday relative to non-holiday periods. A
3-week interval was utilized for Christmas/New Years. Generalized binomial mod-
els were fit over time and adjusted for potential confounders including age, race,
gender, dialysis vintage and vascular access. RESULTS: From 2006-2009, we ob-
served a higher proportion ofmissed sessions over Thanksgiving andChristmas. In
particular, Christmas was associated with a 5.8-fold (0.218 vs. 0.038, p0.0001) and
3.7-fold (0.241 vs. 0.065, p0.0001) higher proportion compared to the non-holiday
periods in 2008 and 2009, respectively. Conversely, the proportion of missed ses-
sions during Memorial Day, Independence Day, and Labor Day did not differ from
non-holidays. Thanksgiving (OR: 1.21, 95% CI 1.10, 1.32) and Christmas (OR: 3.88,
95% CI (3.68, 4.09) were both associatedwith a higher odds ofmissed sessions, even
after adjusting for potential confounders. CONCLUSIONS: The Thanksgiving and
Christmas travel periods were associated with a higher likelihood of missed dial-
ysis sessions. Increased travel away from dialysis facilities, overeating, and higher
fluid intake may all contribute, suggesting a continued need for vigilant patient
communication during holidays to help mitigate the economic and adverse im-
pacts of missed dialysis sessions. Further research should verify the association in
larger samples and assess the economic impact of missed hemodialysis sessions.
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